Key result
Semuloparin significantly reduced the composite of symptomatic deep-vein thrombosis, non-fatal pulmonary embolism, or VTE-related death by 64% compared to placebo (p<0.0001).
Why the study?
Does semuloparin reduce VTE or VTE-related death in cancer patients initiating chemotherapy?
Population
3,212 patients with metastatic or locally advanced cancer of lung, pancreas, stomach, colon-rectum, bladder…
Comparison
Semuloparin 20 mg once-daily subcutaneous until… vs Placebo until change of chemotherapy.
Design
RCT, randomized
Follow-up
median treatment duration approximately 3.5 months
Authors
Loading...
Supports semuloparin prophylaxis in cancer patients starting chemotherapy without raising major bleeding; extends thromboprophylaxis evidence to ambulatory oncology.
RCT (n=3,212)
Does semuloparin reduce VTE or VTE-related death in cancer patients initiating chemotherapy?
Effect estimate: 64% reduction
p-value: p=<0.0001
In cancer patients initiating chemotherapy, semuloparin significantly reduced VTE or VTE-related death by 64% without a significant increase in major bleeding.
George et al. (2011) conducted an RCT in Cancer (n=3,212). Semuloparin vs. Placebo was evaluated on composite of symptomatic deep-vein thrombosis, any non-fatal pulmonary embolism, or VTE-related death (64% reduction, p=<0.0001). Semuloparin significantly reduced the composite of symptomatic deep-vein thrombosis, non-fatal pulmonary embolism, or VTE-related death by 64% compared to placebo (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: